This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J Hepatol 2015; 62: S121-30. doi: 10.1016/j.jhep.2015.01.003BoschJGroszmannRJShahVHEvolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatmentsJ Hepatol201562S1213010.1016/j.jhep.2015.01.003451983325920081Open DOISearch in Google Scholar
de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension. J Hepatol 2015; 63: 743-52. doi: 10.1016/j.jhep.2015.05.022deFranchis RBavenoVI FacultyExpanding consensus in portal hypertensionJ Hepatol2015637435210.1016/j.jhep.2015.05.02226047908Open DOISearch in Google Scholar
Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50: 923-8. doi: 10.1016/j.jhep.2009.01.014RipollCGroszmannRJGarcia-TsaoGBoschJGraceNBurroughsAet alHepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosisJ Hepatol200950923810.1016/j.jhep.2009.01.014372114619303163Open DOISearch in Google Scholar
Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, García-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2022; 76: 681-93. doi: 10.1016/J.JHEP.2021.11.018ReigMFornerARimolaJFerrer-FàbregaJBurrelMGarcía-CriadoAet alBCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging systemThe 2022 update. J Hepatol2022766819310.1016/J.JHEP.2021.11.018Open DOISearch in Google Scholar
Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236. doi: 10.1016/j.jhep.2018.03.019GallePRFornerALlovetJMMazzaferroVPiscagliaFRaoulJLet alEASL Clinical Practice Guidelines: management of hepatocellular carcinomaJ Hepatol20186918223610.1016/j.jhep.2018.03.01929628281Open DOISearch in Google Scholar
Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol 2012; 57: 421-9. doi: 10.1016/j.jhep.2012.01.031VanBeers BEPastorCMHussainHKPrimovist, Eovist: what to expect?J Hepatol201257421910.1016/j.jhep.2012.01.03122504332Open DOISearch in Google Scholar
Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging – correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-26. doi: 10.1148/radiol.10092214KitaoAZenYMatsuiOGabataTKobayashiSKodaWet alHepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging – correlation with molecular transporters and histopathologic featuresRadiology20102568172610.1148/radiol.1009221420663969Open DOISearch in Google Scholar
Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013; 267: 776-86. doi: 10.1148/radiol.13120775ChoiJWLeeJMKimSJYoonJHBaekJHHanJKet alHepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarkerRadiology20132677768610.1148/radiol.1312077523401584Open DOISearch in Google Scholar
Ricke J, Seidensticker M. Molecular imaging and liver function assessment by hepatobiliary MRI. J Hepatol 2016; 65: 1081-2. doi: 10.1016/j. jhep.2016.10.004RickeJSeidenstickerMMolecular imaging and liver function assessment by hepatobiliary MRIJ Hepatol2016651081210.1016/j.jhep.2016.10.00427729223Open DOISearch in Google Scholar
Kukuk GM, Schaefer SG, Fimmers R, Hadizadeh DR, Ezziddin S, Spengler U, et al. Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. Eur Radiol 2014; 24: 2482-90. doi: 10.1007/s00330-014-3291-xKukukGMSchaeferSGFimmersRHadizadehDREzziddinSSpenglerUet alHepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function testsEur Radiol20142424829010.1007/s00330-014-3291-x25030459Open DOISearch in Google Scholar
Kobi M, Paroder V, Flusberg M, Rozenblit AMM, Chernyak V. Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase? Clin Radiol 2017; 72: 55-62. doi: 10.1016/j. crad.2016.10.004KobiMParoderVFlusbergMRozenblitAMMChernyakVLimitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase?Clin Radiol201772556210.1016/j.crad.2016.10.00427842889Open DOISearch in Google Scholar
Okada M, Murakami T, Kuwatsuru R, Nakamura Y, Isoda H, Goshima S, et al. Biochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA-enhanced MR images: a multicenter study. Radiology 2016; 281: 474-83. doi: 10.1148/ radiol.2016151061OkadaMMurakamiTKuwatsuruRNakamuraYIsodaHGoshimaSet alBiochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA-enhanced MR images: a multicenter studyRadiology20162814748310.1148/radiol.201615106127195437Open DOISearch in Google Scholar
Zhang W, Wang X, Miao Y, Hu C, Zhao W. Liver function correlates with liver-to-portal vein contrast ratio during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MR at 3 Tesla. Abdom Radiol 2018; 43: 2262-9. doi: 10.1007/s00261-018-1462-yZhangWWangXMiaoYHuCZhaoWLiver function correlates with liver-to-portal vein contrast ratio during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MR at 3 TeslaAbdom Radiol2018432262910.1007/s00261-018-1462-y29476347Open DOISearch in Google Scholar
Öcal O, Peynircioglu B, Loewe C, van Delden O, Vandecaveye V, Gebauer B, et al. Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. Eur Radiol 2021; 32: 1320-9. doi: 10.1007/s00330-021-08218-9ÖcalOPeynirciogluBLoeweCvanDelden OVandecaveyeVGebauerBet alCorrelation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trialEur Radiol2021321320910.1007/s00330-021-08218-9879502634467453Open DOISearch in Google Scholar
Liang M, Zhao J, Xie B, Li C, Yin X, Cheng L, et al. MR liver imaging with Gd-EOB-DTPA: The need for different delay times of the hepatobiliary phase in patients with different liver function. Eur J Radiol 2016; 85: 546-52. doi: 10.1016/j.ejrad.2015.12.015LiangMZhaoJXieBLiCYinXChengLet alMR liver imaging with Gd-EOB-DTPA: The need for different delay times of the hepatobiliary phase in patients with different liver functionEur J Radiol2016855465210.1016/j.ejrad.2015.12.01526860666Open DOISearch in Google Scholar
Ippolito D, Famularo S, Giani A, Orsini EB, Pecorelli A, Pinotti E, et al. Estimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI. Dig Liver Dis 2019; 51: 1438-45. doi: 10.1016/J.DLD.2019.04.009IppolitoDFamularoSGianiAOrsiniEBPecorelliAPinottiEet alEstimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRIDig Liver Dis20195114384510.1016/J.DLD.2019.04.009Open DOISearch in Google Scholar
Yoon JH, Choi JI, Jeong YY, Schenk A, Chen L, Laue H, et al. Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. J Hepatol 2016; 65: 1155-62. doi: 10.1016/j.jhep.2016.07.024YoonJHChoiJIJeongYYSchenkAChenLLaueHet alPre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCCJ Hepatol20166511556210.1016/j.jhep.2016.07.02427476767Open DOISearch in Google Scholar
Yoon JH, Lee JM, Kang H, Ahn SJ, Yang H, Kim E, et al. Quantitative assessment of liver function by using Gadoxetic Acid-enhanced MRI: hepatocyte uptake ratio. Radiology 2019; 290: 125-33. doi: 10.1148/radiol.2018180753YoonJHLeeJMKangHAhnSJYangHKimEet alQuantitative assessment of liver function by using Gadoxetic Acid-enhanced MRI: hepatocyte uptake ratioRadiology20192901253310.1148/radiol.201818075330375932Open DOISearch in Google Scholar
Yamada S, Shimada M, Morine Y, Imura S, Ikemoto T, Saito Y, et al. A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging. PLoS One 2019; 14: e0210579. doi: 10.1371/journal.pone.0210579YamadaSShimadaMMorineYImuraSIkemotoTSaitoYet alA new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imagingPLoS One201914e021057910.1371/journal.pone.0210579634714730682046Open DOISearch in Google Scholar
Notake T, Shimizu A, Kubota K, Ikehara T, Hayashi H, Yasukawa K, et al. Hepatocellular uptake index obtained with gadoxetate disodium-enhanced magnetic resonance imaging in the assessment future liver remnant function after major hepatectomy for biliary malignancy. BJS Open 2021; 55(4): zraa048. doi: 10.1093/BJSOPEN/ZRAA048NotakeTShimizuAKubotaKIkeharaTHayashiHYasukawaKet alHepatocellular uptake index obtained with gadoxetate disodium-enhanced magnetic resonance imaging in the assessment future liver remnant function after major hepatectomy for biliary malignancyBJS Open2021554zraa04810.1093/BJSOPEN/ZRAA048Open DOISearch in Google Scholar
Daire JL, Leporq B, Vilgrain V, Van Beers BE, Schmidt S, Pastor CM. Liver perfusion modifies Gd-DTPA and Gd-BOPTA hepatocyte concentrations through transfer clearances across sinusoidal membranes. Eur J Drug Metab Pharmacokinet 2017; 42: 657-67. doi: 10.1007/s13318-016-0382-xDaireJLLeporqBVilgrainVVanBeers BESchmidtSPastorCMLiver perfusion modifies Gd-DTPA and Gd-BOPTA hepatocyte concentrations through transfer clearances across sinusoidal membranesEur J Drug Metab Pharmacokinet2017426576710.1007/s13318-016-0382-x27778300Open DOISearch in Google Scholar
Ayuso C, Forner A, Darnell A, Rimola J, García-Criado Á, Bianchi L, et al. Prospective evaluation of gadoxetic-acid MR for the diagnosis of HCC in newly detected nodules ≤ 2 cm in cirrhosis. Liver Int 2019; 39: 1281-91. doi: 10.1111/liv.14133AyusoCFornerADarnellARimolaJGarcía-CriadoÁBianchiLet alProspective evaluation of gadoxetic-acid MR for the diagnosis of HCC in newly detected nodules ≤ 2 cm in cirrhosisLiver Int20193912819110.1111/liv.1413331077539Open DOISearch in Google Scholar
Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012; 56: 103-8. doi: S0168-8278(11)00606-4 [pii] 10.1016/j.jhep.2011.06.027LlopEBerzigottiAReigMEriceEReverterESeijoSet alAssessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumorsJ Hepatol2012561038S0168-8278(11)00606-4[pii]10.1016/j.jhep.2011.06.027Open DOISearch in Google Scholar
Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, et al. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 2016; 26: 921-31. doi: 10.1007/ s00330-015-3900-3NeriEBaliMABa-SsalamahABoraschiPBrancatelliGAlvesFCet alESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agentsEur Radiol2016269213110.1007/s00330-015-3900-3477814326194455Open DOISearch in Google Scholar
Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, et al. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: where are we? J Magn Reson Imaging 2017; 45: 646-59. doi: 10.1002/jmri.25518Ba-SsalamahABastatiNWibmerAFragnerRHodgeJCTraunerMet alHepatic gadoxetic acid uptake as a measure of diffuse liver disease: where are we?J Magn Reson Imaging2017456465910.1002/jmri.2551827862590Open DOISearch in Google Scholar
Motosugi U, Ichikawa T, Oguri M, Sano K, Sou H, Muhi A, et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 2011; 29: 1047-52. doi: 10.1016/j.mri.2011.05.007MotosugiUIchikawaTOguriMSanoKSouHMuhiAet alStaging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio indexMagn Reson Imaging20112910475210.1016/j.mri.2011.05.00721775085Open DOISearch in Google Scholar
Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, et al. Staging hepatic fibrosis: comparison of Gadoxetate Disodium-enhanced and diffusion-weighted MR imaging – preliminary observations. Radiology 2011; 259: 142-50. doi: 10.1148/radiol.10100621WatanabeHKanematsuMGoshimaSKondoHOnozukaMMoriyamaNet alStaging hepatic fibrosis: comparison of Gadoxetate Disodium-enhanced and diffusion-weighted MR imaging – preliminary observationsRadiology20112591425010.1148/radiol.1010062121248234Open DOISearch in Google Scholar
Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol 2017; 42: 179-90. doi: 10.1007/s00261-016-0841-5BesaCLewisSPandharipandePVChhatwalJKamathACooperNet alHepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acidAbdom Radiol2017421799010.1007/s00261-016-0841-527448609Open DOISearch in Google Scholar
Vietti Violi N, Taouli B. Abbreviated MRI for HCC surveillance: is it ready for clinical use? Eur Radiol 2020; 30: 4147-9. doi: 10.1007/s00330-020-06904-8ViettiVioli NTaouliBAbbreviated MRI for HCC surveillance: is it ready for clinical use?Eur Radiol2020304147910.1007/s00330-020-06904-832394280Open DOISearch in Google Scholar
Canellas R, Rosenkrantz AB, Taouli B, Sala E, Saini S, Pedrosa I, et al. Abbreviated MRI protocols for the abdomen. Radiographics 2019; 39: 744-58. doi: 10.1148/rg.2019180123CanellasRRosenkrantzABTaouliBSalaESainiSPedrosaIet alAbbreviated MRI protocols for the abdomenRadiographics2019397445810.1148/rg.201918012330901285Open DOISearch in Google Scholar
Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021; 31: 5615-28. doi: 10.1007/S00330-020-07637-4KohDMBa-SsalamahABrancatelliGFananapazirGFielMIGoshimaSet alConsensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imagingEur Radiol20213156152810.1007/S00330-020-07637-4827079933523304Open DOISearch in Google Scholar
Hanada K, Nakai K, Tanaka H, Suzuki F, Kumada H, Ohno Y, et al. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet 2012; 27: 301-6. doi: 10.2133/ dmpk.dmpk-11-rg-077HanadaKNakaiKTanakaHSuzukiFKumadaHOhnoYet alEffect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis developmentDrug Metab Pharmacokinet201227301610.2133/dmpk.dmpk-11-rg-07722166890Open DOISearch in Google Scholar
Thakkar N, Slizgi JR, Brouwer KLR. Effect of liver disease on hepatic transporter expression and function. J Pharm Sci 2017; 106: 2282-94. doi: 10.1016/j.xphs.2017.04.053ThakkarNSlizgiJRBrouwerKLREffect of liver disease on hepatic transporter expression and functionJ Pharm Sci201710622829410.1016/j.xphs.2017.04.053561451128465155Open DOISearch in Google Scholar
Shin NY, Kim MJ, Lim JS, Park MS, Chung YE, Choi JY, et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 2012; 22: 864-71. doi: 10.1007/ s00330-011-2333-xShinNYKimMJLimJSParkMSChungYEChoiJYet alAccuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastasesEur Radiol2012228647110.1007/s00330-011-2333-x22108766Open DOISearch in Google Scholar
Yoneda N, Matsui O, Ikeno H, Inoue D, Yoshida K, Kitao A, et al. Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome. Abdom Imaging 2015; 40: 3099-103. doi: 10.1007/s00261-015-0503-zYonedaNMatsuiOIkenoHInoueDYoshidaKKitaoAet alCorrelation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndromeAbdom Imaging201540309910310.1007/s00261-015-0503-z26187715Open DOISearch in Google Scholar
Asenbaum U, Ba-Ssalamah A, Mandorfer M, Nolz R, Furtner J, Reiberger T, et al. Effects of portal hypertension on Gadoxetic Acid-Enhanced liver magnetic resonance: diagnostic and prognostic implications. Invest Radiol 2017; 52: 462-9. doi: 10.1097/RLI.0000000000000366AsenbaumUBa-SsalamahAMandorferMNolzRFurtnerJReibergerTet alEffects of portal hypertension on Gadoxetic Acid-Enhanced liver magnetic resonance: diagnostic and prognostic implicationsInvest Radiol201752462910.1097/RLI.000000000000036628622247Open DOISearch in Google Scholar
Hectors SJ, Bane O, Kennedy P, Cuevas J, Thung S, Fischman A, et al. Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen. Eur Radiol 2021; 31: 4804-12. doi: 10.1007/s00330-020-07495-0HectorsSJBaneOKennedyPCuevasJThungSFischmanAet alNoninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleenEur Radiol20213148041210.1007/s00330-020-07495-033411050Open DOISearch in Google Scholar
Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma. Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014; 273: 30-50. doi: 1148/ radiol.14132362ChoiJYLeeJMSirlinCBCT and MR imaging diagnosis and staging of hepatocellular carcinomaPart II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology201427330501148/radiol.14132362Open DOISearch in Google Scholar
Renzulli M, Golfieri R, Bologna Liver Oncology Group (BLOG). Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease. J Gastroenterol Hepatol 2016; 31: 69-80. doi: 10.1111/jgh.13150RenzulliMGolfieriRBolognaLiver Oncology Group (BLOG)Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver diseaseJ Gastroenterol Hepatol201631698010.1111/jgh.1315026312574Open DOISearch in Google Scholar
Renzulli M, Biselli M, Brocchi S, Granito A, Vasuri F, Tovoli F, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 2018; 67: 1674-82. doi: 10.1136/ gutjnl-2017-315384RenzulliMBiselliMBrocchiSGranitoAVasuriFTovoliFet alNew hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithmGut20186716748210.1136/gutjnl-2017-31538429437912Open DOISearch in Google Scholar
Ding Y, Rao SX, Chen C, Li R, Zeng MS. Assessing liver function in patients with HBV-related HCC: a comparison of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI. Eur Radiol 2015; 25: 1392-8. doi: 10.1007/ s00330-014-3542-xDingYRaoSXChenCLiRZengMSAssessing liver function in patients with HBV-related HCC: a comparison of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging with DWIEur Radiol2015251392810.1007/s00330-014-3542-x25523455Open DOISearch in Google Scholar
Haimerl M, Verloh N, Zeman F, Fellner C, Müller-Wille R, Schreyer AG, et al. Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI. PLoS One 2013; 8: e85658 doi: 10.1371/JOURNAL.PONE.0085658HaimerlMVerlohNZemanFFellnerCMüller-WilleRSchreyerAGet alAssessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRIPLoS One20138e8565810.1371/JOURNAL.PONE.0085658Open DOISearch in Google Scholar